Human papillomaviruses (HPV) cause most cases of cervical cancer and large proportions of vaginal, vulvar, anal, penile, and oropharyngeal cancers. HPV vaccines could dramatically reduce the incidence of HPV-associated cancers and other conditions among both females and males, but the uptake of vaccines has fallen short of target levels.
Concerted, coordinated efforts by multiple public and private organizations are needed to increase HPV vaccine uptake and achieve the vaccines' potential to prevent cancers. CDC estimates that increasing HPV vaccination rates from current levels to 80 percent would prevent an additional 53,000 future cervical cancer cases among girls who now are 12 years old or younger over the course of their lifetimes. This estimate does not include the thousands of U.S. cases of other HPV-associated cancers that likely also would be prevented within the same timeframe.
The September NCI Research to Reality cyber-seminar will present key goals and high priority research interventions to increase HPV vaccine uptake. We also will highlight promising interventions that through a variety of strategies have created substantive changes in accelerating HPV vaccine uptake.
As always, part of the webinar will be dedicated to your questions. We look forward to you engaging with the presenters, and sharing your own experiences.